Traditional Chinese Herbs Found to Suppress Progression of Diabetes
By LabMedica International staff writers Posted on 28 Jan 2014 |

Image: According to a new study, the ability of Tianqi, a Chinese herbal medicine, to reduce the risk of developing diabetes, is similar to that of diabetes drugs, metformin and acarbose (Photo courtesy of the University of Chicago).
Traditional Chinese herbal medicines have the potential for slowing the progression from prediabetes to a clinical diabetes diagnosis, according to new research.
An individual who has developed raised blood sugar levels is diagnosed with prediabetes, but glucose levels have not yet been elevated to the point of developing type 2 diabetes. Individuals who are prediabetic are faced with an increased risk of developing type 2 diabetes as well as stroke and heart disease.
“With diabetes evolving into a serious public health burden worldwide, it is crucial to take steps to stem the flood of cases,” said one of the study’s authors, Chun-Su Yuan, MD, PhD, from the University of Chicago (IL, USA). “Patients often struggle to make the necessary lifestyle changes to control blood sugar levels, and current medications have limitations and can have adverse gastrointestinal side effects. Traditional Chinese herbs may offer a new option for managing blood sugar levels, either alone or in combination with other treatments.”
During the double-blind, randomized, placebo-controlled trial, 389 participants at 11 research sites in China were randomly assigned to take either a capsule containing a combination of 10 Chinese herbal medicines or a placebo. Study participants, for the duration of one year, took capsules of either the Chinese herb mixture, called Tianqi, or the placebo three times per day before meals. All participants received one month of lifestyle education at the beginning of the trial and met with nutritionists several times during the study. Study participants’ glucose tolerance was measured on a quarterly basis.
At the end of the trial, 36 participants in the Tianqi group and 56 in the placebo group had developed diabetes. The analysis found taking Tianqi reduced the risk of diabetes by 32.1% compared with the placebo, after adjusting for age and gender. The overall reduction in risk was similar to that found in studies of diabetes medications acarbose and metformin, and study participants reported few side effects from the Tianqi herbs. Tianqi includes various herbs that have been shown to lower blood glucose levels and increase regulation of blood glucose levels after meals.
“Few controlled clinical trials have examined traditional Chinese medicine’s impact on diabetes, and the findings from our study showed this approach can be very useful in slowing the disease’s progression,” said one of the study’s lead authors, Xiaolin Tong, MD, PhD, from Guang’anmen Hospital (Beijing, China). “More research is needed to evaluate the role Chinese herbal medicine can play in preventing and controlling diabetes.”
The findings were published February 2014, in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism (JCEM).
Related Links:
University of Chicago
Guang’anmen Hospital
An individual who has developed raised blood sugar levels is diagnosed with prediabetes, but glucose levels have not yet been elevated to the point of developing type 2 diabetes. Individuals who are prediabetic are faced with an increased risk of developing type 2 diabetes as well as stroke and heart disease.
“With diabetes evolving into a serious public health burden worldwide, it is crucial to take steps to stem the flood of cases,” said one of the study’s authors, Chun-Su Yuan, MD, PhD, from the University of Chicago (IL, USA). “Patients often struggle to make the necessary lifestyle changes to control blood sugar levels, and current medications have limitations and can have adverse gastrointestinal side effects. Traditional Chinese herbs may offer a new option for managing blood sugar levels, either alone or in combination with other treatments.”
During the double-blind, randomized, placebo-controlled trial, 389 participants at 11 research sites in China were randomly assigned to take either a capsule containing a combination of 10 Chinese herbal medicines or a placebo. Study participants, for the duration of one year, took capsules of either the Chinese herb mixture, called Tianqi, or the placebo three times per day before meals. All participants received one month of lifestyle education at the beginning of the trial and met with nutritionists several times during the study. Study participants’ glucose tolerance was measured on a quarterly basis.
At the end of the trial, 36 participants in the Tianqi group and 56 in the placebo group had developed diabetes. The analysis found taking Tianqi reduced the risk of diabetes by 32.1% compared with the placebo, after adjusting for age and gender. The overall reduction in risk was similar to that found in studies of diabetes medications acarbose and metformin, and study participants reported few side effects from the Tianqi herbs. Tianqi includes various herbs that have been shown to lower blood glucose levels and increase regulation of blood glucose levels after meals.
“Few controlled clinical trials have examined traditional Chinese medicine’s impact on diabetes, and the findings from our study showed this approach can be very useful in slowing the disease’s progression,” said one of the study’s lead authors, Xiaolin Tong, MD, PhD, from Guang’anmen Hospital (Beijing, China). “More research is needed to evaluate the role Chinese herbal medicine can play in preventing and controlling diabetes.”
The findings were published February 2014, in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism (JCEM).
Related Links:
University of Chicago
Guang’anmen Hospital
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples
Channels
Clinical Chemistry
view channel
New Clinical Chemistry Analyzer Designed to Meet Growing Demands of Modern Labs
A new clinical chemistry analyzer is designed to provide outstanding performance and maximum efficiency, without compromising affordability, to meet the growing demands of modern laboratories.... Read more
New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
Nucleic acid amplification tests (NAATs) play a key role in diagnosing a wide range of infectious diseases. These tests are generally known for their high sensitivity and specificity, and they can be developed... Read moreMolecular Diagnostics
view channel
Newly-Cleared Technology a Game Changer for Diagnosis of Lyme Disease
Lyme disease is one of the fastest-growing infectious diseases, with approximately 476,000 cases diagnosed annually in the United States. The symptoms of Lyme disease, such as fever, headache, fatigue,... Read more
Innovative Liquid Biopsy Test Uses RNA to Detect Early-Stage Cancer
Detecting and diagnosing cancer, particularly in its early stages, remains a significant challenge. Liquid biopsies offer a promising non-invasive alternative to traditional biopsies, which require removing... Read moreHematology
view channel
Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read moreImmunology
view channel
World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment
Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more
Blood Test Detects Organ Rejection in Heart Transplant Patients
Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Liquid Biopsy Approach to Transform Diagnosis, Monitoring and Treatment of Lung Cancer
Lung cancer continues to be a major contributor to cancer-related deaths globally, with its biological complexity and diverse regulatory processes making diagnosis and treatment particularly difficult.... Read more
Computational Tool Exposes Hidden Cancer DNA Changes Influencing Treatment Resistance
Structural changes in tumor DNA are among the most damaging genetic alterations in cancer, yet they often go undetected, particularly when tissue samples are degraded or of low quality. These hidden genomic... Read moreMicrobiology
view channel
Viral Load Tests Can Help Predict Mpox Severity
Mpox is a viral infection that causes flu-like symptoms and a characteristic rash, which evolves significantly over time and varies between patients. The disease spreads mainly through direct contact with... Read more
Gut Microbiota Analysis Enables Early and Non-Invasive Detection of Gestational Diabetes
Gestational diabetes mellitus is a common metabolic disorder marked by abnormal glucose metabolism during pregnancy, typically emerging in the mid to late stages. It significantly heightens the risk of... Read morePathology
view channel
AI Tool Enhances Interpretation of Tissue Samples by Pathologists
Malignant melanoma, a form of skin cancer, is diagnosed by pathologists based on tissue samples. A crucial aspect of this process is estimating the presence of tumor-infiltrating lymphocytes (TILs), immune... Read more
AI-Assisted Technique Tracks Cells Damaged from Injury, Aging and Disease
Senescent cells, which stop growing and reproducing due to injury, aging, or disease, play a critical role in wound repair and aging-related diseases like cancer and heart disease. These cells, however,... Read more
Novel Fluorescent Probe Shows Potential in Precision Cancer Diagnostics and Fluorescence-Guided Surgery
Hepatocellular carcinoma (HCC), a common type of liver cancer, is difficult to diagnose early and accurately due to the limitations of current diagnostic methods. Glycans, carbohydrate structures present... Read moreTechnology
view channel
Low-Cost Biosensing Technology Detects Disease Biomarkers in Minutes
Rapid at-home tests for diseases like COVID-19 have become increasingly popular for their convenience, but they come with a major drawback: they are less sensitive than the tests performed in medical settings.... Read more
AI Tool Could Help Identify Specific Gut Bacterial Targets for Treatment of Diseases
The human body hosts trillions of bacteria, particularly in the gut, which have a significant role in digestion and various other aspects of health. These gut bacteria produce a variety of metabolites... Read moreIndustry
view channel
Quanterix Completes Acquisition of Akoya Biosciences
Quanterix Corporation (Billerica, MA, USA) has completed its previously announced acquisition of Akoya Biosciences (Marlborough, MA, USA), paving the way for the creation of the first integrated solution... Read more
Lunit and Microsoft Collaborate to Advance AI-Driven Cancer Diagnosis
Lunit (Seoul, South Korea) and Microsoft (Redmond, WA, USA) have entered into a collaboration to accelerate the delivery of artificial intelligence (AI)-powered healthcare solutions. In conjunction with... Read more